Montelucaste Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelucaste Ratiopharm, is a leukotriene receptor antagonist presented as a tablet for oral use. It is employed to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children, while providing symptom relief as part of a long‑term management plan.

GNH USA supplies Montelucaste Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. The company maintains a robust distribution network across the EU and other global markets.

Montelukast, a leukotriene receptor antagonist, is used in respiratory and allergic disease management. - Asthma: Improves control of chronic symptoms and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: Prevents airway narrowing triggered by physical activity. - Allergic rhinitis: Alleviates nasal congestion, sneezing, and itchy eyes associated with seasonal allergies.

Montelukast is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Cough: occasional dry cough. - Abdominal pain: mild discomfort. - Diarrhea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Allergic reactions: hives, swelling, or anaphylaxis. - Neuropsychiatric events: agitation, depression, or suicidal thoughts. - Hepatotoxicity: elevated liver enzymes. - Angioedema: swelling of face, lips, or tongue. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: confirm diagnosis of asthma, exercise‑induced bronchoconstriction, or allergic rhinitis before initiating therapy. - Age considerations: use in children according to approved labeling; monitor growth in pediatric patients. - Hepatic function: assess liver status in patients with known hepatic impairment. - Neuropsychiatric monitoring: observe for mood changes, depression, or suicidal ideation during treatment. - Drug interactions: review concomitant medications for potential interactions that may affect efficacy or safety. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and direct sunlight.

Montelukast may interact with other medicines, altering its effectiveness or increasing the risk of adverse effects.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can increase montelukast plasma levels. - Ketoconazole: potent CYP3A4 inhibitor may raise drug exposure.

Moderate Interactions (Monitor Closely): - Phenobarbital: enzyme inducer that may reduce montelukast concentrations. - Carbamazepine: moderate CYP3A4 inducer potentially decreasing efficacy. - Warfarin: possible alteration of anticoagulant effect; monitor INR. - Oral contraceptives: may slightly increase montelukast levels; observe for side effects.